Search Results - "Sueptitz, J."

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors by Wagener-Ryczek, S., Heydt, C., Sueptitz, J., Michels, S., Falk, M., Alidousty, C., Fassunke, J., Tiemann, M., Heukamp, L., Wolf, J., Buettner, R., Merkelbach-Bruse, S.

Get full text

3006 Broad implementation of next generation sequencing based lung cancer genotyping in clinical routine within a nationwide health care provider network in Germany by Kostenko, A, Kron, F, Scheffler, M, Michels, S, Sueptitz, J, Fischer, R, Merkelbach-Bruse, S, Scheel, A, De-Mary, P, Glossmann, J.P, Buettner, R, Wolf, J

Get full text

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM) by Janning, M., Süptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J.-L., Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I., Brändlein, S., Hummel, H.-D., Wiesweg, M., Schildhaus, H.-U., Stratmann, J.A., Sebastian, M., Alt, J., Buth, J., Esposito, I., Berger, J., Tögel, L., Saalfeld, F.C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A.M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J., Loges, S., Simon, Ronald, Sauter, Guido, Volk, Alexander, Neumann, Jens, Klauschen, Frederick, Weichert, Wilko, Kalhori, Naser, Lüthen, Reinhard, Stöhr, Robert, Schubart, Chistoph, Wacker, Heidemarie, Fuchs, Florian, Hartmann, Nils, Graf, Stefanie, Brandts, Christian, Wild, Peter, Demes, Melanie, Reis, Henning, Rohde, Gernot

“…Atypical EGFR mutations occur in 10%-30% of non-small-cell lung cancer (NSCLC) patients with EGFR mutations and their sensitivity to classical epidermal growth…”
Get full text

134PMutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors by Wagener-Ryczek, S, Heydt, C, Sueptitz, J, Michels, S, Falk, M, Alidousty, C, Fassunke, J, Tiemann, M, Heukamp, L, Wolf, J, Buettner, R, Merkelbach-Bruse, S

Get full text